BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,092,690 | -18.1% | 104,197 | -1.8% | 0.02% | -8.3% |
| Q2 2023 | $8,663,310 | -14.2% | 106,129 | -22.0% | 0.02% | -20.0% |
| Q1 2023 | $10,100,004 | +16.3% | 136,137 | +30.0% | 0.03% | +7.1% |
| Q4 2022 | $8,681,431 | -6.8% | 104,747 | +219.2% | 0.03% | -6.7% |
| Q3 2022 | $9,319,000 | -31.7% | 32,813 | -16.7% | 0.03% | -16.7% |
| Q2 2022 | $13,649,000 | -18.2% | 39,375 | +2.2% | 0.04% | +2.9% |
| Q1 2022 | $16,687,000 | +14.2% | 38,534 | +36.5% | 0.04% | +25.0% |
| Q4 2021 | $14,606,000 | -4.1% | 28,233 | -10.2% | 0.03% | -12.5% |
| Q3 2021 | $15,237,000 | +76.7% | 31,445 | +64.2% | 0.03% | +77.8% |
| Q2 2021 | $8,621,000 | +363.0% | 19,146 | +292.8% | 0.02% | +350.0% |
| Q1 2021 | $1,862,000 | +19.9% | 4,874 | -0.3% | 0.00% | 0.0% |
| Q4 2020 | $1,553,000 | +23.2% | 4,891 | -3.9% | 0.00% | +33.3% |
| Q3 2020 | $1,261,000 | -4.3% | 5,091 | +2.0% | 0.00% | -25.0% |
| Q2 2020 | $1,318,000 | +34.9% | 4,991 | -3.1% | 0.00% | +33.3% |
| Q1 2020 | $977,000 | -16.5% | 5,151 | -3.4% | 0.00% | 0.0% |
| Q4 2019 | $1,170,000 | +12.6% | 5,331 | +0.4% | 0.00% | 0.0% |
| Q3 2019 | $1,039,000 | -6.9% | 5,311 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $1,116,000 | -19.0% | 5,351 | -22.9% | 0.00% | -25.0% |
| Q1 2019 | $1,378,000 | +33.5% | 6,941 | -2.7% | 0.00% | +33.3% |
| Q4 2018 | $1,032,000 | -29.1% | 7,131 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $1,456,000 | +35.3% | 7,131 | -1.9% | 0.00% | +33.3% |
| Q2 2018 | $1,076,000 | -3.9% | 7,271 | -1.9% | 0.00% | 0.0% |
| Q1 2018 | $1,120,000 | +14.2% | 7,413 | -2.1% | 0.00% | 0.0% |
| Q4 2017 | $981,000 | +7.9% | 7,573 | +0.7% | 0.00% | 0.0% |
| Q3 2017 | $909,000 | +4.6% | 7,521 | +1.7% | 0.00% | 0.0% |
| Q2 2017 | $869,000 | +16.5% | 7,392 | +0.7% | 0.00% | 0.0% |
| Q1 2017 | $746,000 | -63.8% | 7,342 | -63.4% | 0.00% | -66.7% |
| Q4 2016 | $2,061,000 | -22.8% | 20,042 | -17.8% | 0.01% | -18.2% |
| Q3 2016 | $2,670,000 | -1.4% | 24,383 | +1.6% | 0.01% | 0.0% |
| Q2 2016 | $2,707,000 | +10.6% | 24,003 | -7.3% | 0.01% | +10.0% |
| Q1 2016 | $2,448,000 | +0.4% | 25,903 | -4.4% | 0.01% | +11.1% |
| Q4 2015 | $2,439,000 | -54.4% | 27,103 | -53.1% | 0.01% | -57.1% |
| Q3 2015 | $5,344,000 | -50.0% | 57,793 | -46.8% | 0.02% | -43.2% |
| Q2 2015 | $10,687,000 | -30.4% | 108,533 | -29.1% | 0.04% | -30.2% |
| Q1 2015 | $15,357,000 | +475.8% | 153,123 | +430.5% | 0.05% | +488.9% |
| Q4 2014 | $2,667,000 | – | 28,863 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |